Aspirin to Target Arterial Events in Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4633 participants.

Also called NCT03796156

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 4,633 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03796156
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03796156. Randomized; single masking; primary purpose prevention. Start 2019-02-25 (actual); primary completion 2024-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aspirin to Target Arterial Events in Chronic Kidney Disease
Acronym
ATTACK
Condition
Chronic Kidney Diseases
Condition
Cardiovascular Diseases
Condition
Bleeding
Intervention (Drug)
Aspirin
Lead sponsor
University of Southampton (class: other)
Collaborator
University of Nottingham (class: other)
Collaborator
University of Warwick (class: other)
Collaborator
Nottingham University Hospitals NHS Trust (class: other)
Collaborator
East Kent Hospitals University NHS Foundation Trust (class: other government)
Collaborator
University of Durham (class: other)
Collaborator
Epsom and St Helier University Hospitals NHS Trust (class: other)

Record details

Record id
cardio:ct-nct03796156
Content hash
1e97bd8017ba9da80ac4a1783c465939fb2584f2958cbf729579f7157f3170fa